Fulcrum therapeutics announces departure of chief medical officer

Cambridge, mass., july 11, 2022 (globe newswire) -- fulcrum therapeutics, inc. (nasdaq: fulc), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that chief medical officer, christopher morabito, m.d., will be leaving the company, effective july 13, 2022. judith dunn, ph.d., president of research and development will provide interim leadership while the executive search for a new cmo is ongoing.
FULC Ratings Summary
FULC Quant Ranking